NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Exact Sciences Corporation (NASDAQ: EXAS)

 
EXAS Technical Analysis
5
As on 20th Nov 2025 EXAS STOCK Price closed @ 100.67 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 54.11 & Strong Buy for SHORT-TERM with Stoploss of 48.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

EXASSTOCK Price

Open 101.63 Change Price %
High 101.87 1 Day 14.49 16.81
Low 100.56 1 Week 33.17 49.14
Close 100.67 1 Month 41.21 69.31
Volume 67805923 1 Year 55.12 121.01
52 Week High 71.93 | 52 Week Low 40.31
 
NASDAQ USA Most Active Stocks
LPTX 2.05 365.91%
AMRS 0.14 100.00%
WBA 11.98 0.50%
NVDA 180.64 -3.15%
LMDX 0.02 0.00%
ONDS 6.28 -16.27%
TSLA 395.23 -2.17%
OPEN 6.16 -7.92%
PLUG 1.89 -0.53%
AKTS 0.04 0.00%
 
NASDAQ USA Top Gainers Stocks
MRIN 3450.00 383233.34%
MRIN 3450.00 383233.34%
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
LPTX 2.05 365.91%
NDRAW 0.03 200.00%
HCVIU 9.00 159.37%
GLSPT 33.43 138.62%
 
NASDAQ USA Top Losers Stocks
SRNE 0.00 -100.00%
COMSP 0.00 -100.00%
FPAY 0.01 -94.74%
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
SWSSU 1.06 -89.40%
ZIVOW 0.06 -85.00%
ORGS 0.15 -83.52%
OTRK 0.07 -78.79%
ACAQ-UN 2.50 -73.49%
 
 
EXAS
Daily Charts
EXAS
Intraday Charts
Whats New @
Bazaartrend
EXAS
Free Analysis
 
EXAS Important Levels Intraday
RESISTANCE103.19
RESISTANCE102.38
RESISTANCE101.88
RESISTANCE101.38
SUPPORT99.96
SUPPORT99.46
SUPPORT98.96
SUPPORT98.15
 
EXAS Forecast November 2025
4th UP Forecast132.75
3rd UP Forecast122.46
2nd UP Forecast116.1
1st UP Forecast109.74
1st DOWN Forecast91.6
2nd DOWN Forecast85.24
3rd DOWN Forecast78.88
4th DOWN Forecast68.59
 
EXAS Weekly Forecast
4th UP Forecast106.82
3rd UP Forecast104.85
2nd UP Forecast103.63
1st UP Forecast102.41
1st DOWN Forecast98.93
2nd DOWN Forecast97.71
3rd DOWN Forecast96.49
4th DOWN Forecast94.52
 
EXAS Forecast2025
4th UP Forecast222.19
3rd UP Forecast183.22
2nd UP Forecast159.13
1st UP Forecast135.04
1st DOWN Forecast66.3
2nd DOWN Forecast42.21
3rd DOWN Forecast18.12
4th DOWN Forecast-20.85
 
 
EXAS Other Details
Segment EQ
Market Capital 16636064768.00
Sector Healthcare
Industry Diagnostics & Research
Offical website >
 
EXAS Address
EXAS
 
EXAS Latest News
 
Your Comments and Response on Exact Sciences Corporation
 
EXAS Business Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Address: 5505 Endeavor Lane, Madison, WI, United States, 53719
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service